Targeting hedgehog signaling in cancer: research and clinical developments
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Since its first description in Drosophila by Drs Nusslein-Volhard and Wieschaus in 1980, hedgehog (Hh) signaling has been implicated in regulation of cell differentiation, proliferation, tissue polarity, stem cell maintenance, and carcinogenesis. The first link of Hh signaling to cancer was established through studies of Gorlin syndrome in 1996 by two independent teams. Later, it was shown that Hh signaling may be involved in many types of cancer, including skin, leukemia, lung, brain, and gastrointestinal cancers. In early 2012, the US Food and Drug Administration approved the clinical use of Hh inhibitor Erivedge/vismodegib for treatment of locally advanced and metastatic basal cell carcinomas. With further investigation, it is possible to see more clinical applications of Hh signaling inhibitors. In this review, we will summarize major advances in the last 3 years in our understanding of Hh signaling activation in human cancer, and recent developments in preclinical and clinical studies using Hh signaling inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Echelard, Y., Epstein, D. J., St-Jacques, B., Shen, L., Mohler, J., McMahon, J. A., & McMahon, A. P. (1993) · Cell · doi:10.1016/0092-8674(93)90627-3 · Cited by 2,154
Altered Neural Cell Fates and Medulloblastoma in Mouse patched Mutants
Goodrich, L. V., Milenković, L., Higgins, K. M., & Scott, M. P. (1997) · Science · doi:10.1126/science.277.5329.1109 · Cited by 1,696 · cited 1×
“For example, activated Hh signaling can drive development of BCCs, medulloblastomas, rhabdomyosarcoma, GIST, and Barrett’s esophagus, 118,119,122,124,128,129 and Hh signaling in these lesions serves as the tumor driver, at least in the mouse models.”
Vertebrate Smoothened functions at the primary cilium
Corbit, K. C., Aanstad, P., Singla, V., Norman, A. R., Stainier, D. Y. R., & Reiter, J. F. (2005) · Nature · doi:10.1038/nature04117 · Cited by 1,481
Cilia and Hedgehog responsiveness in the mouse
Huangfu, D., & Anderson, K. V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505328102 · Cited by 820
Patched acts catalytically to suppress the activity of Smoothened
Taipale, J., Cooper, M. K., Maiti, T., & Beachy, P. A. (2002) · Nature · doi:10.1038/nature00989 · Cited by 794 · cited 1×
“Studies from cultured cells indicate that PTC inhibits SMO at a substochiometric concentration.(33) Hh-interacting protein (HIP) can compete with PTC on Hh binding, resulting in negative regulation of Hh signaling.”
Canettieri, G., Di Marcotullio, L., Greco, A., Coni, S., Antonucci, L., Infante, P., Pietrosanti, L., De Smaele, E., Ferretti, E., Miele, E., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2013 · Cited by 322
Cited by
Liang, G., Liu, M., Wang, Q., Shen, Y., Mei, H., Li, D., & Liu, W. (2017) · Oncotarget · doi:10.18632/oncotarget.15324 · Cited by 78
“The link between Hedgehog (Hh) signaling pathway and human cancers has long been recognized [27].”
BackgroundTreatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity
Guy, C. D., Suzuki, A., Abdelmalek, M. F., Burchette, J. L., Diehl, A. M., & CRN, F. T. N. (2015) · Hepatology · doi:10.1002/hep.27235 · Cited by 72
“Clinical proof-ofconcept studies should be feasible because several small molecule inhibitors of the Hh pathway have already been approved for use as cancer chemotherapeutics.(42) A number of drugs that have Food and Drug Administration (FDA) approval for other indications are also capable of blocking Hh signaling and…”
BackgroundGai, X., Tu, K., Li, C., Lu, Z., Roberts, L. R., & Zheng, X. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.76 · Cited by 54
RetractedIntervention in the Context of Development: Pathways Toward New Treatments
Veenstra-VanderWeele, J., & Warren, Z. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.232 · Cited by 34
“The FMR1 gene was identified in FXS about 20 years before the first clinical trials were initiated, a similar time window to cancer therapeutics (Fischgrabe and Wulfing, 2008; Xie et al, 2013).”
Background
Metadata
- Authors
- Xie, J., Bartels, C. M., Gu, D., & Barton, S. W.
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2013-10
- Volume
- 6
- Pages
- 1425
- ISSN
- 1178-6930 (ISSN-L)
- OpenAlex
- W2051120887
- Cited by
- 66
- References
- 6
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting hedgehog signaling in cancer: research and clinical developments. https://app.cochat.ai/papers/10.2147/ott.s34678
- The paper
- Xie, J., Bartels, C. M., Gu, D., & Barton, S. W. (2013). Targeting hedgehog signaling in cancer: research and clinical developments. OncoTargets and Therapy. https://doi.org/10.2147/ott.s34678
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.